Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report)’s share price rose 4.4% on Wednesday . The stock traded as high as $6.96 and last traded at $6.40. Approximately 197,623 shares changed hands during trading, a decline of 56% from the average daily volume of 445,152 shares. The stock had previously closed at $6.13.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Kazia Therapeutics in a report on Friday, July 12th.
Check Out Our Latest Analysis on Kazia Therapeutics
Kazia Therapeutics Stock Performance
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Stories
- Five stocks we like better than Kazia Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is the Shanghai Stock Exchange Composite Index?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- ESG Stocks, What Investors Should Know
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
